These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 24471924)

  • 1. Current strategies for treatment of relapsed/refractory multiple myeloma.
    Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
    Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
    Ashjian E; Redic K
    J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Management of multiple myeloma in the relapsed/refractory patient].
    Tabayashi T
    Rinsho Ketsueki; 2019; 60(9):1257-1264. PubMed ID: 31597851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How is patient care for multiple myeloma advancing?
    Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A
    Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
    Nijhof IS; van de Donk NWCJ; Zweegman S; Lokhorst HM
    Drugs; 2018 Jan; 78(1):19-37. PubMed ID: 29188449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
    Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
    Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
    Moreau P
    Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
    Moreau P
    Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current treatment of refractory and relapsed multiple myeloma].
    Sasaki M
    Rinsho Ketsueki; 2016; 57(10):2084-2095. PubMed ID: 27795518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future agents and treatment directions in multiple myeloma.
    Ocio EM; Mitsiades CS; Orlowski RZ; Anderson KC
    Expert Rev Hematol; 2014 Feb; 7(1):127-41. PubMed ID: 24350987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
    van de Donk NW; Lokhorst HM
    Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
    Boudreault JS; Touzeau C; Moreau P
    Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
    Dimopoulos MA; Richardson P; Lonial S
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):460-473. PubMed ID: 35148975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment strategy for relapsed or refractory myeloma according to the new Guidelines].
    Ozaki S
    Rinsho Ketsueki; 2018; 59(10):2178-2188. PubMed ID: 30305524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
    Varga C; Laubach JP; Anderson KC; Richardson PG
    Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
    Moreau P; de Wit E
    Br J Haematol; 2017 Oct; 179(2):198-218. PubMed ID: 28556890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
    Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
    Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of relapsed multiple myeloma after autologous stem cell transplant.
    Holstein SA; Richardson PG; Laubach JP; McCarthy PL
    Biol Blood Marrow Transplant; 2015 May; 21(5):793-8. PubMed ID: 25652690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.